Aurinia has announced a 45% workforce reduction to bolster sales of the lupus drug Lupkynis and advance the development of ...

Joining me on the call this morning are Peter Greenleaf, Aurinia's President and Chief Executive Officer; Joe Miller, our ...

After an activist investor revolted against the leadership team at Aurinia Pharmaceuticals, the CEO in question is resorting to restructuring. | After an activist investor revolted against the ...

Aurinia Pharmaceuticals Reports Q3 and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development ...

Reports Q3 revenue $67.8M, consensus $57.69M. “We are pleased to report continued strong momentum through the first nine months of the year,” stated CEO Peter Greenleaf. “Going forward, our ...

“We are pleased to report continued strong momentum through the first nine months of the year,” stated Peter Greenleaf, President and Chief Executive Officer of Aurinia. “Going ...

Aurinia Pharmaceuticals Inc. (NASDAQ: NASDAQ:AUPH) demonstrated a significant financial turnaround in its Third Quarter 2024 Earnings Call, with CEO Peter Greenleaf, CFO Joe Miller, and CMO Dr. Greg ...

In the statement accompanying the Q3 results, CEO Peter Greenleaf said the workforce reduction would “strengthen Aurinia’s financial position and provide more flexibility to engage in future ...

Joining me on the call this morning are Peter Greenleaf, Aurinia's President and Chief Executive Officer; Joe Miller, our Chief Financial Officer; and Dr. Greg Keenan, our Chief Medical Officer.

Joining me on the call this morning are Peter Greenleaf, Aurinia’s President and Chief Executive Officer; Joe Miller, our Chief Financial Officer; and Dr. Greg Keenan, our Chief Medical Officer.